"Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Descriptor ID |
D011658
|
| MeSH Number(s) |
C08.381.765
|
| Concept/Terms |
Pulmonary Fibrosis- Pulmonary Fibrosis
- Pulmonary Fibroses
- Fibroses, Pulmonary
- Fibrosis, Pulmonary
Alveolitis, Fibrosing- Alveolitis, Fibrosing
- Alveolitides, Fibrosing
- Fibrosing Alveolitides
- Fibrosing Alveolitis
- Hamman-Rich Syndrome
- Hamman Rich Syndrome
- Syndrome, Hamman-Rich
|
Below are MeSH descriptors whose meaning is more general than "Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Pulmonary Fibrosis".
This graph shows the total number of publications written about "Pulmonary Fibrosis" by people in this website by year, and whether "Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 4 | 1 | 5 |
| 2005 | 2 | 1 | 3 |
| 2006 | 3 | 0 | 3 |
| 2007 | 7 | 0 | 7 |
| 2008 | 2 | 3 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 6 | 2 | 8 |
| 2012 | 1 | 3 | 4 |
| 2013 | 6 | 0 | 6 |
| 2014 | 3 | 2 | 5 |
| 2015 | 4 | 1 | 5 |
| 2016 | 4 | 0 | 4 |
| 2017 | 5 | 1 | 6 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pulmonary Fibrosis" by people in Profiles.
-
Reduced Cathepsin L expression and secretion into the extracellular milieu contribute to lung fibrosis in systemic sclerosis. Rheumatology (Oxford). 2023 03 01; 62(3):1306-1316.
-
The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis. Int J Mol Sci. 2023 Feb 03; 24(3).
-
Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis. Arthritis Rheumatol. 2023 03; 75(3):438-448.
-
Soluble ECM promotes organotypic formation in lung alveolar model. Biomaterials. 2022 04; 283:121464.
-
Multiple subregions within the caveolin-1 scaffolding domain inhibit fibrosis, microvascular leakage, and monocyte migration. PLoS One. 2022; 17(2):e0264413.
-
Effect of lung pericyte-like cell ablation on the bleomycin model of injury and repair. Am J Physiol Lung Cell Mol Physiol. 2022 04 01; 322(4):L607-L616.
-
Identification of Impacted Pathways and Transcriptomic Markers as Potential Mediators of Pulmonary Fibrosis in Transgenic Mice Expressing Human IGFBP5. Int J Mol Sci. 2021 Nov 22; 22(22).
-
Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis. Am J Physiol Lung Cell Mol Physiol. 2021 01 01; 320(1):L29-L40.
-
Long noncoding RNA H19X is a key mediator of TGF-?-driven fibrosis. J Clin Invest. 2020 09 01; 130(9):4888-4905.
-
Pressure overload generates a cardiac-specific profile of inflammatory mediators. Am J Physiol Heart Circ Physiol. 2020 08 01; 319(2):H331-H340.